Top Story Today
AstraZeneca's IL-33 Blocker Wins Again on the Target Everyone Left for Dead
Roche failed on IL-33. Sanofi and Regeneron's contradictory trial results tanked stocks across the sector. The entire drug target was declared dead. Then AstraZeneca's tozorakimab posted its third consecutive Phase 3 win in COPD, hitting the primary endpoint in the MIRANDA trial. The secret: blocking both forms of IL-33, not just one. The drug works across eosinophil levels and smoking status, potentially doubling the eligible population for COPD biologics. AstraZeneca is projecting $3 to $5 billion in peak annual sales.
Why it matters: This validates a mechanism of action the industry wrote off and could create an entirely new category of biologic treatment for millions of COPD patients who currently have no biologic options at all.
Read more →Clinical Wins
Novo Nordisk's Sickle Cell Pill Cut Pain Crises by Nearly Half
The GLP-1 giant you know for Ozempic just posted positive Phase 2 results for a once-daily sickle cell disease pill. Etavopivat reduced vaso-occlusive crises by 46% versus placebo and doubled the time before a patient's first pain episode. Filing is planned for late 2026.
Read more →Funding & Financings
The $700M Biotech Wall Street Rejected Is Filing for Round Two
Odyssey Therapeutics pulled its IPO in 2025 when the biotech market froze. Now it's back with a fresh S-1, targeting $100 million on the Nasdaq. The company raised $213 million privately in the interim, pushing total venture funding past $700 million. With Q1 2026 biotech IPO proceeds at their highest since Q4 2021, the timing might finally cooperate.
Read more →